This animation, created by GSK, explains Plasmodium vivax malaria
Around 8.5 million clinical infections every year are caused by P. vivax.1 Many of these are relapses from existing infections that occur in the absence of new infective mosquito bites. This occurs because P. vivax parasites can lie dormant in the liver as hypnozoites, reactivating weeks, months or even years after initial infection.
MMV and GlaxoSmithKline (GSK) have partnered to develop Krintafel (tafenoquine) for the radical cure (prevention of relapse) of Plasmodium vivax (P. vivax) malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection.
Krintafel, approved by the US FDA on 20 July 2018, is the first new treatment for Plasmodium vivax malaria in over 60 years. Read the press release.
1. World Health Organization. World Malaria Report 2017.